Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated (Ligand) is a biotechnology company that operates with a business model focused on developing or acquiring revenue generating assets and coupling them with a lean corporate cost structure. The Company's technology CAPTISOL is a formulation technology that has enabled seven United States Food and Drug Administration (FDA) approved products including Kyprolis and Noxafil-IV and is being developed in several clinical-stage partner programs. The Company is engaged in the development of product candidates indicated for the treatment of diseases, such as hepatitis, multiple myeloma, muscle wasting, Alzheimer’s disease, dyslipidemia, diabetes, anemia, epilepsy, focal segmental glomerulosclerosis (FSGS) and osteoporosis.
Company Growth (employees)
Type
Public
HQ
San Diego, US
Size (employees)
22 (est)+5%
Website
ligand.com
Ligand Pharmaceuticals is headquartered in San Diego, US

Key People at Ligand Pharmaceuticals

John L. Higgins

John L. Higgins

CEO
David J. Mangelsdorf

David J. Mangelsdorf

Team Member
Ronald M. Evans

Ronald M. Evans

Team Member

Ligand Pharmaceuticals Office Locations

Ligand Pharmaceuticals has an office in San Diego
San Diego, US (HQ)
200 11119 N Torrey Pines Rd

Ligand Pharmaceuticals Metrics

Ligand Pharmaceuticals Financial Metrics

Revenue (2016)

$109 m

Revenue growth (2015-16), %

52%

Gross profit

$103.4 m

Gross profit margin (2016), %

95%

Net income (2016)

($1.6 m)

Market capitalization (28-Apr-2017)

$2.3 b

Closing share price (28-Apr-2017)

$111.2

Cash (31-Dec-2016)

$18.8 m
Ligand Pharmaceuticals's current market capitalization is $2.3 b.
Ligand Pharmaceuticals's revenue was reported to be $109 m in FY, 2016 which is a 52% increase from the previous period.
FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

$49 m$64.5 m$71.9 m$109 m

Revenue growth, %

32%11%52%

Cost of goods sold

$5.6 m

Gross profit

$43.2 m$55.4 m$66.1 m$103.4 m

Gross profit Margin, %

88%86%92%95%

Operating expense total

$34 m$44.9 m$44.6 m$65.1 m

EBIT

$14.9 m$19.6 m$27.3 m($2.4 m)

EBIT margin, %

31%30%38%(2%)

Interest expense

$2.1 m$4.9 m$11.8 m$12.2 m

Income tax expense

($10.3 m)

Net Income

$11.4 m$10.9 m$254.9 m($1.6 m)
FY, 2013FY, 2014FY, 2015FY, 2016

Cash

$11.6 m$160.2 m$97.4 m$18.8 m

Accounts Receivable

$2.2 m$12.6 m$6.2 m$14.7 m

Inventories

$1.4 m$269 k$1.6 m$1.9 m

Current Assets

$24.9 m$185.2 m$215.6 m$163.1 m

PP&E

$867 k$486 k$372 k$1.8 m

Goodwill

$12.2 m$12.2 m$12.2 m$72.2 m

Total Assets

$104.7 m$258 m$533.9 m$601.6 m

Accounts Payable

$4 m$7.7 m$4.1 m$2.7 m

Current Liabilities

$28.9 m$22.8 m$20.8 m$227.1 m

Additional Paid-in Capital

$718 m$680.7 m$701.5 m$769.7 m

Retained Earnings

($671.3 m)($659.3 m)($402 m)($431.1 m)

Total Equity

$24.4 m$304.4 m$341.3 m

Financial Leverage

10.6 x1.8 x1.8 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

$11.4 m$10.9 m$254.9 m($1.6 m)

Depreciation and Amortization

$2.7 m$2.7 m$2.6 m$10.6 m

Accounts Receivable

$2.4 m($10 m)$6.5 m($8.5 m)

Inventories

$646 k$4.4 m($401 k)($244 k)

Accounts Payable

Cash From Operating Activities

$20.7 m$20.6 m$41.7 m$63 m

Purchases of PP&E

($6 k)($93 k)($1.9 m)

Cash From Investing Activities

($5 m)($2 m)($112.9 m)($143.2 m)

Long-term Borrowings

($19.6 m)($9.4 m)

Cash From Financing Activities

($16.5 m)$130 m$8.4 m$1.5 m

Interest Paid

$1.8 m$494 k$1.8 m$1.8 m

Income Taxes Paid

$26 k$18 k$28 k$38 k

Ligand Pharmaceuticals Market Value History

Ligand Pharmaceuticals Online Presence

Ligand Pharmaceuticals News

Ligand Pharmaceuticals Company Life

You may also be interested in